129 related articles for article (PubMed ID: 34993673)
21. Dual time point
Yamagishi Y; Koiwai T; Yamasaki T; Einama T; Fukumura M; Hiratsuka M; Kono T; Hayashi K; Ishida J; Ueno H; Tsuda H
BMC Cancer; 2019 Nov; 19(1):1146. PubMed ID: 31775675
[TBL] [Abstract][Full Text] [Related]
22. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
[TBL] [Abstract][Full Text] [Related]
23. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
[TBL] [Abstract][Full Text] [Related]
24. Use of
Iqbal SA; Goel S; Aggarwal A; Gupta N; Gupta M; Durga G; Talwar V; Singh S
J Gastrointest Cancer; 2021 Sep; 52(3):1073-1080. PubMed ID: 33128717
[TBL] [Abstract][Full Text] [Related]
25. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
[TBL] [Abstract][Full Text] [Related]
26. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
[TBL] [Abstract][Full Text] [Related]
27. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma.
Yoshida N; Baba Y; Shigaki H; Harada K; Iwatsuki M; Sakamoto Y; Miyamoto Y; Kurashige J; Kosumi K; Tokunaga R; Watanabe M; Baba H
Int J Clin Oncol; 2016 Dec; 21(6):1071-1078. PubMed ID: 27255393
[TBL] [Abstract][Full Text] [Related]
28. The maximum standardized uptake value increment calculated by dual-time-point
Yonezawa N; Minamikawa T; Kitajima K; Takahashi Y; Sasaki R; Nibu KI; Komori T
Nagoya J Med Sci; 2017 Feb; 79(2):189-198. PubMed ID: 28626254
[TBL] [Abstract][Full Text] [Related]
29. Role of
Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
[TBL] [Abstract][Full Text] [Related]
30. MRI and FDG-PET for assessment of response to neoadjuvant chemotherapy in locally advanced rectal cancer.
Aiba T; Uehara K; Nihashi T; Tsuzuki T; Yatsuya H; Yoshioka Y; Kato K; Nagino M
Ann Surg Oncol; 2014 Jun; 21(6):1801-8. PubMed ID: 24531702
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy.
Nakatani M; Migita K; Matsumoto S; Wakatsuki K; Ito M; Nakade H; Kunishige T; Kitano M; Kanehiro H
Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575242
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy.
Bae SJ; Ahn SG; Ji JH; Chu CH; Kim D; Lee J; Park S; Cha C; Jeong J
J Breast Cancer; 2022 Dec; 25(6):485-499. PubMed ID: 36479600
[TBL] [Abstract][Full Text] [Related]
33. Correlation Between Standardized Uptake Value in Preneoadjuvant and Postneoadjuvant Chemoradiotherapy and Tumor Regression Grade in Patients With Locally Advanced Esophageal Cancer.
Baksh K; Prithviraj G; Kim Y; Hoffe S; Shridhar R; Coppola D; Centeno B; Pimiento J; Meredith K; Almhanna K
Am J Clin Oncol; 2018 Mar; 41(3):254-258. PubMed ID: 26703814
[TBL] [Abstract][Full Text] [Related]
34. ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography for Evaluating the Response to Neoadjuvant Chemotherapy in Advanced Esophageal Cancer.
Tani Y; Nakajima M; Kikuchi M; Ihara K; Muroi H; Takahashi M; Domeki Y; Okamoto K; Yamaguchi S; Sasaki K; Tsuchioka T; Sakamoto S; Kato H
Anticancer Res; 2016 Jan; 36(1):367-73. PubMed ID: 26722067
[TBL] [Abstract][Full Text] [Related]
35. Novel Criterion Using Esophageal Major and Minor Axes is Useful to Evaluate the Therapeutic Effect and Prognosis After Neoadjuvant Chemotherapy Followed by Surgery in Locally Advanced Esophageal Cancer.
Yoshida N; Taniyama Y; Murakami K; Horinouchi T; Takahashi K; Shiraishi S; Eto K; Kamei T; Matsubara H; Baba H
Ann Surg Oncol; 2021 Dec; 28(13):8474-8482. PubMed ID: 34260005
[TBL] [Abstract][Full Text] [Related]
36. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
37. To Compare and Determine the Diagnostic Accuracy of [
Sharma N; Purkayastha A; Vishwanath S; Jaiswal P
World J Nucl Med; 2018; 17(2):79-85. PubMed ID: 29719481
[TBL] [Abstract][Full Text] [Related]
38. Impact of CT-assessed changes in tumor size after neoadjuvant chemotherapy on pathological response and survival of patients with esophageal squamous cell carcinoma.
Matsumoto S; Wakatsuki K; Nakade H; Kunishige T; Miyao S; Tsujimoto A; Tatsumi T; Sho M
Langenbecks Arch Surg; 2022 May; 407(3):965-974. PubMed ID: 34989856
[TBL] [Abstract][Full Text] [Related]
39. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of the standardized uptake value maximum change calculated by dual-time-point (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer.
Jin F; Zhu H; Fu Z; Kong L; Yu J
Onco Targets Ther; 2016; 9():2993-9. PubMed ID: 27284249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
